Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
about
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation; a Japanese multicenter experience.The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia: A Case Report.
P2860
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Safety and efficacy of daclata ...... atients with renal impairment.
@en
type
label
Safety and efficacy of daclata ...... atients with renal impairment.
@en
prefLabel
Safety and efficacy of daclata ...... atients with renal impairment.
@en
P2093
P2860
P50
P356
P1433
P1476
Safety and efficacy of daclata ...... patients with renal impairment
@en
P2093
Atsushi Nagasaka
Fumiyuki Sato
Izumi Tsunematsu
Junichi Yoshida
Katsumi Terashita
Ken Furuya
Kenichi Kumagai
Koji Ogawa
P2860
P304
P356
10.1111/HEPR.12851
P577
2017-01-31T00:00:00Z